Skip to Main Content
Skip Nav Destination

Next-Gen PARP Inhibitor Effective in Breast Cancer

April 11, 2024

Abstract: New data from the PETRA clinical trial suggest that the PARP1 inhibitor saruparib induces durable responses in patients with HER-negative breast cancer. Researchers found that the maximum tolerated dose of 90 mg per day produced an overall response rate of 46.7% and median duration of response of 5.6 months. The values for a dose of 60 mg were 48.4% and 7.3 months, leading the researchers to choose this as the optimal dose.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal